Root of Polygonum cuspidatum extract reduces progression of diabetes-induced mesangial cell dysfunction via inhibition of platelet-derived growth factor-BB (PDGF-BB) and interaction with its receptor in streptozotocin-induced diabetic rats

BMC Complementary and Alternative Medicine

Jin Sook Kim¹  Yun Mi Lee¹  Kyuhyung Jo¹  Chan-Sik Kim¹  Junghyun Kim¹  Eunjin Sohn¹ 

[1] Korean Medicine Based Herbal Drug Development Group, Herbal Medicine Research Division, Korea Institute of Oriental Medicine (KIOM), 1672 Yusengdaero, Yuseong-gu, Daejeon 305-811, South Korea

关键词: Polygonum cuspidatum;    Glomerular proliferation;    Diabetic nephropathy;   

Others  :  1085056
DOI  :  10.1186/1472-6882-14-477

 received in 2014-03-26, accepted in 2014-12-03,  发布年份 2014

【 摘 要 】

Background

Platelet-derived growth factor–BB (PDGF-BB) is highly expressed in the renal tissues of patients with diabetic nephropathy, and it plays an important role in the initiation and progression of diabetic nephropathy. The aim of this study was to evaluate the protective effects of root of Polygonum cuspidatum extract (PCE) on early renal glomerular proliferation in streptozotocin (STZ)-induced diabetic rats.

Methods

PCE (100, 350 mg/kg/day) was administered to diabetic rats for 16 weeks. Blood glucose and albuminuria were measured. Renal histology, α-smooth muscle actin (α-SMA), and proliferating cell nuclear antigen (PCNA) expression levels were also examined.

Results

After 16 weeks of treatment with PCE, severe hyperglycemia and albuminuria were observed in the diabetic rats. The expressions levels of α-SMA and PCNA proteins were significantly increased in the glomeruli of the diabetic rats. The expression levels of PDGF-BB and its receptor expressions were greatly increased in the glomeruli of the diabetic rats. However, PCE markedly reduced albuminuria in the diabetic rats. PCE inhibited α-SMA and PCNA up-regulation and ameliorated PDGF-BB and PEGFR-ß protein expression in the diabetic rats. In addition, the binding of PDGF-BB/PDGFR-ß was inhibited by PCE as shown by an in vitro assay.

Conclusions

These results suggest that PCE has an inhibitory effect on mesangial proliferation in diabetic renal tissues via the inhibition of the interaction of PDGF-BB with its receptor. PCE may have beneficial effects in preventing the progression of diabetic nephropathy.

【 授权许可】

   
2014 Sohn et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ: PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 2001, 59(4):1324-1332.
• [2]Nakagawa H, Sasahara M, Haneda M, Koya D, Hazama F, Kikkawa R: Immunohistochemical characterization of glomerular PDGF B-chain and PDGF beta-receptor expression in diabetic rats. Diabetes Res Clin Pract 2000, 48(2):87-98.
• [3]Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME: Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol 2001, 12(10):2098-2107.
• [4]Langham RG, Kelly DJ, Maguire J, Dowling JP, Gilbert RE, Thomson NM: Over-expression of platelet-derived growth factor in human diabetic nephropathy. Nephrol Dial Transplant 2003, 18(7):1392-1396.
• [5]Wang QY, Guan QH, Chen FQ: The changes of platelet-derived growth factor-BB (PDGF-BB) in T2DM and its clinical significance for early diagnosis of diabetic nephropathy. Diabetes Res Clin Pract 2009, 85(2):166-170.
• [6]Gilbert RE, Zhang Y, Williams SJ, Zammit SC, Stapleton DI, Cox AJ, Krum H, Langham R, Kelly DJ: A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat. PLoS One 2012, 7(10):e47160.
• [7]Yamashita H, Nagai Y, Takamura T, Nohara E, Kobayashi K: Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism 2002, 51(4):403-408.
• [8]Pandhare R, Sangameswaran B: Extract of Adenanthera pavonina L. seed reduces development of diabetic nephropathy in streptozotocin-induced diabetic rats. Avicenna J Phytomed 2012, 2(4):233-242.
• [9]Tesch GH, Allen TJ: Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 2007, 12(3):261-266.
• [10]Flynn ER, Marbury DC, Sawyer RT, Lee J, Teutsch C, Kauser K, Maric-Bilkan C: Amlodipine reduces inflammation despite promoting albuminuria in the streptozotocin-induced diabetic Rat. Nephron extra 2012, 2(1):205-218.
• [11]Bralley EE, Greenspan P, Hargrove JL, Wicker L, Hartle DK: Topical anti-inflammatory activity of Polygonum cuspidatum extract in the TPA model of mouse ear inflammation. J Inflamm (Lond) 2008, 5:1. BioMed Central Full Text
• [12]Ban SH, Kwon YR, Pandit S, Lee YS, Yi HK, Jeon JG: Effects of a bio-assay guided fraction from Polygonum cuspidatum root on the viability, acid production and glucosyltranferase of mutans streptococci. Fitoterapia 2010, 81(1):30-34.
• [13]Zhang H, Li C, Kwok ST, Zhang QW, Chan SW: A review of the pharmacological effects of the dried root of (Hu Zhang) and its constituents. Evid Based Complement Alternat Med 2013, 2013:208349.
• [14]Lu Y, Jeong YT, Li X, Kim MJ, Park PH, Hwang SL, Son JK, Chang HW: Emodin isolated from polygoni cuspidati radix inhibits TNF-alpha and IL-6 release by blockading NF-kappaB and MAP kinase pathways in mast cells stimulated with PMA plus A23187. Biomol Ther 2013, 21(6):435-441.
• [15]Fan HT, Ding SL, Lin HS: [Pharmacological of Polygoni cuspidati rhizoma]. Zhongguo Zhong Yao Za Zhi 2013, 38(15):2545-2548.
• [16]Zhou YX, Chen J, Li JP, Wang YL, Jin XD: Chinese medicinal herbs in treating model rats with hepatic fibrosis. Afr J Tradit Complement Altern Med 2010, 7(2):104-108.
• [17]Brosius FC 3rd: New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord 2008, 9(4):245-254.
• [18]Leask A, Abraham DJ: TGF-beta signaling and the fibrotic response. FASEB J 2004, 18(7):816-827.
• [19]Wynn TA, Ramalingam TR: Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012, 18(7):1028-1040.
• [20]Kim CS, Sohn EJ, Kim YS, Jung DH, Jang DS, Lee YM, Kim DH, Kim JS: Effects of KIOM-79 on hyperglycemia and diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats. J Ethnopharmacol 2007, 111(2):240-247.
• [21]Sohn E, Kim J, Kim CS, Kim YS, Jang DS, Kim JS: Extract of the aerial parts of Aster koraiensis reduced development of diabetic nephropathy via anti-apoptosis of podocytes in streptozotocin-induced diabetic rats. Biochem Biophys Res Commun 2010, 391(1):733-738.
• [22]Ricono JM, Xu YC, Arar M, Jin DC, Barnes JL, Abboud HE: Morphological insights into the origin of glomerular endothelial and mesangial cells and their precursors. J Histochem Cytochem 2003, 51(2):141-150.
• [23]Siu B, Saha J, Smoyer WE, Sullivan KA, Brosius FC 3rd: Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: prevention by lipoic acid treatment. BMC Nephrol 2006, 7:6. BioMed Central Full Text
• [24]Jarad G, Miner JH: Update on the glomerular filtration barrier. Curr Opin Nephrol Hypertens 2009, 18(3):226-232.
• [25]Ma ST, Liu DL, Deng JJ, Niu R, Liu RB: Effect of arctiin on glomerular filtration barrier damage in STZ-induced diabetic nephropathy rats. Phyto Res 2013, 27(10):1474-1480.
• [26]Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, Ishigaki Y, Kitada M, Srivastava SP, Koya D: Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 2014, 63(6):2120-2131.
• [27]Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS: Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012, 340(2):248-255.
• [28]Tan Z, Xu Z, Gui Q, Wu W, Yang Y: Gliquidone versus metformin: differential effects on aorta in streptozotocin induced diabetic rats. Chin Med J 2014, 127(7):1298-1303.
• [29]Meyer L, Bohme P, Delbachian I, Lehert P, Cugnardey N, Drouin P, Guerci B: The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 2002, 25(12):2153-2158.
• [30]Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH: Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant 2004, 19(12):2987-2996.
• [31]Ostendorf T, Kunter U, Grone HJ, Bahlmann F, Kawachi H, Shimizu F, Koch KM, Janjic N, Floege J: Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2001, 12(5):909-918.
• [32]Bessa SS, Hussein TA, Morad MA, Amer AM: Urinary platelet-derived growth factor-BB as an early marker of nephropathy in patients with type 2 diabetes: an Egyptian study. Ren Fail 2012, 34(6):670-675.
• [33]Pietras K, Sjoblom T, Rubin K, Heldin CH, Ostman A: PDGF receptors as cancer drug targets. Cancer Cell 2003, 3(5):439-443.
• [34]Mauer SM: Structural-functional correlations of diabetic nephropathy. Kidney Int 1994, 45(2):612-622.
• [35]Geleilete TJ, Costa RS, Dantas M, Coimbra TM: Alpha-smooth muscle actin and proliferating cell nuclear antigen expression in focal segmental glomerulosclerosis: functional and structural parameters of renal disease progression. Braz J Med Biol Res 2001, 34(8):985-991.
• [36]Kuno Y, Iyoda M, Shibata T, Hirai Y, Akizawa T: Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats. Br J Pharmacol 2011, 162(6):1389-1400.
• [37]Park CE, Kim MJ, Lee JH, Min BI, Bae H, Choe W, Kim SS, Ha J: Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med 2007, 39(2):222-229.
• [38]Xue J, Ding W, Liu Y: Anti-diabetic effects of emodin involved in the activation of PPARgamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice. Fitoterapia 2010, 81(3):173-177.
• [39]Ghanim H, Sia CL, Abuaysheh S, Korzeniewski K, Patnaik P, Marumganti A, Chaudhuri A, Dandona P: An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010, 95(9):E1-E8.
• [40]Wu XB, Luo XQ, Gu SY, Xu JH: The effects of Polygonum cuspidatum extract on wound healing in rats. J Ethnopharmacol 2012, 141(3):934-937.
• [41]Zahedi HS, Jazayeri S, Ghiasvand R, Djalali M, Eshraghian MR: Effects of polygonum cuspidatum containing resveratrol on inflammation in male professional basketball players. Int J Prev Med 2013, 4(Suppl 1):S1-S4.
• [42]Kim YS, Lee YM, Kim JH, Kim JS: Polygonum cuspidatum inhibits pancreatic lipase activity and adipogenesis via attenuation of lipid accumulation. BMC Complement Altern Med 2013, 13:282. BioMed Central Full Text
• [43]Ikizler M, Ovali C, Dernek S, Erkasap N, Sevin B, Kaygisiz Z, Kural T: Protective effects of resveratrol in ischemia-reperfusion injury of skeletal muscle: A clinically relevant animal model for lower extremity ischemia. Chin J Physiol 2006, 49(4):204-209.
• [44]Yang J, Zeng Z, Wu T, Yang Z, Liu B, Lan T: Emodin attenuates high glucose-induced TGF-beta1 and fibronectin expression in mesangial cells through inhibition of NF-kappaB pathway. Exp Cell Res 2013, 319(20):3182-3189.
• [45]Gao J, Wang F, Wang W, Su Z, Guo C, Cao S: Emodin suppresses hyperglycemia-induced proliferation and fibronectin expression in mesangial cells via inhibiting cFLIP. PLoS One 2014, 9(4):e93588.
• [46]Xu F, Wang Y, Cui W, Yuan H, Sun J, Wu M, Guo Q, Kong L, Wu H, Miao L: Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: possible roles of Akt/NF-kappaB pathway. Int J Endocrinol 2014, 2014:289327.
• [47]Zhang L, Pang S, Deng B, Qian L, Chen J, Zou J, Zheng J, Yang L, Zhang C, Chen X, Liu Z, Le Y: High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF-kappaB/NADPH oxidase/ROS pathway, which is inhibited by resveratrol. Int J Biochem Cell Biol 2012, 44(4):629-638.